Organization | Austrian Forum Against Cancer

Austrian Forum Against Cancer Report issue

Foundation Phase 2 Phase 3

Organization Overview

First Clinical Trial

1999

NCT00205764

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2010

Timeline

NOW

Now

Alternative names

Austrian Forum agianst Cancer; Wilhelminenspital Vienna, 1st. Med. Department - center for Oncology and Hematology

Active Ingredients

Drugs in Phase 3 Trials (4)

melphalan (alkeran) (2 trials)

prednisone (meticorten) (1 trial)

thalidomide (Thalomid) (1 trial)

urea (4 trials)

Drugs in Phase 2 Trials (3)

bendamustine (treanda) (1 trial)

bortezomib (velcade) (2 trials)

lenalidomide (revlimid) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Multiple Myeloma (Phase 3)

Neoplasms, Plasma Cell (Phase 3)

Renal Insufficiency (Phase 2)

Overview

Highest Phase: Phase 3
# of Trials: 5
# of Trial APIs: 7